Report Highlights

U.S. Closed System Drug Transfer Devices: Market Overview

The U.S. closed system drug transfer device market differs from the global norm because American demand is shaped by federal occupational safety expectations and a concentrated oncology infrastructure rather than by national public tender programmes. The market reached about USD 260 million in 2024, and the United States accounts for roughly 45 percent of worldwide CSTD revenue. Adoption accelerated after USP <800>, the hazardous drug handling standard, took effect on December 1, 2019.

Unlike Europe, where national rules and public tenders dominate, U.S. buyers evaluate CSTDs through hospital value analysis committees and group purchasing contracts. Most units move through hospital outpatient oncology departments, community pharmacies, and FDA-regulated 503B outsourcing facilities. Premium closed-loop systems command several times the unit price of open vial adapters, so market value grows faster than unit volume.

Growth Drivers in U.S. CSTD Adoption

Three country-specific forces lift U.S. demand. First, the Drug Quality and Security Act of 2013 created Section 503B outsourcing facilities, which compound sterile hazardous drugs under FDA oversight and must follow USP <800> handling requirements. Second, the American Cancer Society projected about 2.0 million new U.S. cancer cases in 2024, sustaining infusion volumes across hospital and outpatient settings.

Third, Medicare Part B reimburses most infused chemotherapy at average sales price plus 6 percent, allowing outpatient oncology practices to recover CSTD investment through drug margins. Pharmacy directors also cite nurse exposure liability as a reason to standardize on closed systems, and state boards of pharmacy continue to inspect hazardous drug handling during routine surveys. Together, these drivers position the United States as the largest CSTD adopter globally.

Market Restraints and Entry Barriers

Entry is slowed by FDA 510(k) review, which requires demonstrating substantial equivalence to a predicate device, and by compatibility testing against dozens of oncology drug vials and syringes. Group purchasing organizations such as Vizient and Premier control contract access for most hospital systems, favoring incumbents with established multi-year agreements. New entrants without GPO listings face long trial cycles before value analysis committees approve purchasing.

Pricing pressure adds a second barrier. CSTD costs sit inside hospital supply budgets rather than receiving separate Medicare payment, so buyers compare per-dose cost against nursing time and waste handling. Incumbents including BD with PhaSeal and ICU Medical with ChemoClave hold installed-base advantages, because switching requires retraining pharmacy and nursing staff at each infusion site.

Market Opportunities in the U.S. CSTD Sector

The most accessible near-term opportunity sits in ambulatory infusion centers, which handle a growing share of chemotherapy as payers steer care toward lower-cost outpatient sites. Analysts estimate this channel represents about USD 60 million of 2024 U.S. CSTD demand, growing faster than inpatient hospital pharmacy. Entrants with compact, single-site packages and bundled training can address this segment without GPO access.

A second opportunity lies with 503B outsourcing facilities, which operate under FDA registration and require validated closed-system transfer for sterile batch production. About 80 facilities are registered nationwide, and their validation needs create demand for bundled service contracts covering cleaning, environmental monitoring, and staff certification. Vendors offering these services alongside devices can capture regional chains that lack in-house compliance teams.

Market at a Glance

Leading Market Participants

• Becton Dickinson
• ICU Medical
• Equashield
• Corvida Medical
• Simplivia Healthcare
• Yukon Medical
• Kiel Laboratories
• Vygon
• Fresenius Kabi
• Medline Industries

Regulatory and Policy Environment

The FDA's Center for Devices and Radiological Health clears CSTDs through 510(k) submissions, and the agency's compounding oversight under Section 503B applies to outsourcing facilities. USP <800> took effect December 1, 2019 and references the NIOSH hazardous drug list, while OSHA enforces the Hazard Communication Standard for workplace exposure. State boards of pharmacy and Joint Commission surveyors inspect hospital compliance.

Subsidies are indirect because no federal program funds CSTD purchases directly. Medicare Part B pays acquisition for infused drugs at average sales price plus 6 percent, and Hospital Outpatient Prospective Payment System rules bundle device costs into APC payments. 503B facilities must complete annual FDA registration and submit semiannual product reports, so new entrants should plan for clearance and registration cycles spanning 6 to 12 months.

Long-Term Outlook for U.S. Drug Transfer Device Demand

By 2032, the U.S. closed system drug transfer device market is projected to reach about USD 520 million, growing at a 9.0 percent CAGR from the 2025 base year. Growth will concentrate in ambulatory oncology networks and 503B outsourcing facilities, while hospital inpatient pharmacies standardize on fewer platforms. Per-dose pricing will compress as competitors consolidate.

Competition will shift toward integrated service models that combine devices with validated training, environmental monitoring, and waste management. Vendors that secure multi-year GPO agreements and FDA clearances for expanded drug compatibility will hold stronger positions than single-product entrants. Mid-sized manufacturers will continue consolidating, while established platform suppliers retain the largest installed bases through 2032.